| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
Cell lines | human pulmonary mucoepidermoid carcinoma cell line, NCI-H292 cells |
Preparation method | The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 30 min, 30 μM [1] |
Applications | TAPI-1, tumor necrosis factor ɑ protease inhibitor-1, is an inhibitor of TACE (TNF-α converting enzyme). TAPI-1 inhibits ectodomain shedding of TNF-ɑ, L-selectin, and p55 TNF-ɑ receptor. Pretreating cells with TAPI-1 inhibits PMA-induced EGFR phosphorylation. Besides, TAPI-1 could block TGF-ɑ release and block the production of mucin induced by PMA, PA sup, and LPS [1]. TAPI-1 is also a general matrix metalloproteinase (MMP) and ADAM inhibitor [2]. |
| 产品描述 | TAPI-1 is an inhibitor of tumour necrosis factor with IC50 value of 8.09 μM [1]. TAPI-1 is an inhibitor of TACE/ADAM17 which catalyzes the cleavage of full-length APP to the soluble N-terminal fragment (sAPPα). The release of sAPPα has been reported to be a receptor-coupled process increased by the stimulation of muscarinic receptors. In HEK293 cells, treatment of TAPI-1 resulted in an inhibition of increased sAPPα which was induced by the expressing of M3 subtype. The IC50 values of TAPI-1 in the inhibition of M3-increased sAPPα and constitutive release of sAPPα were 3.61 μM and 8.09 μM, respectively. Besides APP, TAPI-1 was also found to have inhibitory effects on the release of TNF-α, IL6R, TNFRI and TNFRII with IC50 values of 50-100, 5-10, 5-10 and 25-50 mM, respectively [1, 2]. References: |
m.cnreagent.com